Group items tagged

Mayo Clinic Pulmonary Manifestations of Connective Tissue Disorders is organized by Mayo Clinic CME and would be held during Oct 20 - 21, 2017 at The Ritz Carlton, Amelia Island, Fernandina Beach, Florida, United States Of America. The target audience for this medical event for pulmonologists, rheumatologist, and primary care physicians and providers with an interest in pulmonary involvement of connective tissue disorders. This cme conference has been approved with a maximum of 11.75 AMA PRA Category 1 Credits. Course Description : This two-day course provides pulmonologists, rheumatologists, internists and general practitioners with an up-to-date focus on pulmonary manifestations of rheumatologic disorders. From this course, participants gain a better understanding of how to recognize and diagnose interstitial lung disease, pulmonary hypertension and other respiratory problems which are common in autoimmune rheumatologic disorders, and the latest information regarding pathogenic mechanisms, clinical trials and therapeutic modalities. The speakers will be nationally and internationally recognized specialists in the field. Residents and fellows will have the opportunity to participate by submitting original studies for poster presentations. Conference Objectives are : * Review basic clinical and therapeutic aspects of interstitial lung disease and pulmonary hypertension in patients with connective tissue diseases * Improve interpretation skills for laboratory and pulmonary testing pertaining to patients with interstitial lung disease and connective tissue diseases * Identify patients that need a multidisciplinary approach early in the course of the disease * Review up-to-date information about ongoing research in connective tissue disease with patients with autoimmune lung involvement

44th Annual Vascular and Endovascular Issues, Techniques, Horizons (VEITH) Symposium is organized by Cleveland Clinic and would be held during Nov 14 - 18, 2017 at New York Hilton Midtown, New York, United States of America. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Objectives : Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to: * Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease * Summarize the impact of data on therapeutic advances for stroke and carotid disease management * Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease * Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care * Summarize recent data on treatment advances for venous disease and explain their clinical implications * Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors

Infectious Diseases Society of America (IDSA) : IDWeek is organized by Infectious Diseases Society of America (IDSA) and would be held during Oct 04 - 08, 2017 at San Diego Convention Center, San Diego, California, United States Of America. The target audience for this medical event for healthcare professionals in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists, and public health officials, including those who see HIV and pediatric patients. It is a must-attend meeting for professionals who want to stay current, apply state-of-the art science to clinical care, and excel in their own careers. This CME Conference has been approved with a maximum of 41.75 AMA PRA Category 1 Credits.

Alzheimer disease (AD) is a chronic neuro-degenerative disease accounting for almost 70% of dementia cases. The most common symptom being short term memory loss, the disease leads to a decline in self management and behavior with impacts varying per individual. Though, AD is an age related disorder with people above 60 being most likely to be affected, individuals with a history of frequent head injuries, depression, hypertension may also carry a risk. Researchers and scientists are unsure about the cause of Alzheimers but studies have been conducted and they claim that 7 out of 10 cases are genetically caused (e4 allele of gene apolipoprotein E). Additionally, pathophysiological causes (Plaques and neurofibrillary tangles, neuronal death) cannot be ruled out in the disease pathology and progression. AD forms one of the most actively explored and researched areas in the field of medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 2, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

Vascular Interventional Advances Annual Conference (VIVA) is organized by Vascular Interventional Advances (VIVA) and would be held during Nov 11 - 15, 2017 at Wynn Las Vegas, Las Vegas, Nevada, United States of America. TARGET AUDIENCE : The target audience for this CME activity is physicians who specialize in, among other areas, interventional cardiology, interventional radiology, vascular medicine, vascular surgery, cardiothoracic surgery, neurosurgery, podiatry and neuroradiology, as well as fellows, and allied health professionals (including nurses, vascular clinic staff, endovascular operating room staff, catheterization laboratory and angiography suite staff, nurse practitioners, vascular technologists, and physicians assistants). LEARNING OBJECTIVES : At the conclusion of the course, the targeted learners should be able: * Understand the current indications, risks, complications, and outcome of medical, interventional, and surgical therapies for the treatment of peripheral arterial and venous diseases. * Incorporate advanced medical, endovascular, and surgical techniques and approaches into their own practices to improve the care and outcomes of patients. * Implement high quality guidelines based programs to improve the early identification and care of patients with non- cardiac vascular conditions. * Increase knowledge in critical decision-making and the comprehensive spectrum of care for patients with stroke and intracranial and extracranial carotid artery disease. * Improve the delivery of balanced and scientifically valid vascular care in accordance with expert opinion and practice. * Utilize strategies learned from the meeting including endovascular technologies, open surgical techniques, and hybrid approaches, for the treatment of patients with aortic diseases. * To gain and employ decision making and procedural strategies and techniques in patients with aortic and visceral aneurysms, dissections, deep venous thrombosis, venous insufficiency and pu

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 02, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according to a study published online Oct. 11 in the New England Journal of Medicine. Edward Gane, M.D., from Auckland City Hospital in New Zealand, and colleagues conducted a multicenter trial to examine the efficacy and safety of combination treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults with HCV infection and compensated liver disease with severe renal impairment, dependence on dialysis, or both. Participants had stage 4 or 5 chronic kidney disease. One hundred four patients were enrolled in the trial. The researchers found that the sustained virologic response rate was 98 percent. During treatment, none of the patients had virologic failure, and none had a virologic relapse after the end of treatment. Pruritus, fatigue, and nausea were reported in at least 10 percent of the patients. Twenty-four percent of the patients reported serious adverse events. Because of adverse events, four patients discontinued the trial treatment prematurely; three of these had sustained virologic response

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.

As a cardiologist, your expertise includes the diagnosis, treatment and prevention of heart and blood vessel diseases. Patients of all ages may be sent to you, or perhaps you have chosen to specialize in an area like geriatric or pediatric cardiology. And even though you have completed an extensive amount of internal medicine and cardiology education to-date, on-going training requirements must still be fulfilled. We can help you find continuing medical education (CME) courses that are just as specialized as your skill set. Our database of cardiology medical conferences can help you find CME opportunities that meet your needs. In addition to general cardiovascular medicine events, we feature conferences dedicated to specific topics like heart rhythm, echocardiography, hypertension and more. Register for events hosted by leading hospitals in cardiology such as the Cleveland Clinic and the Mayo Clinic. Are you ready to attend your next cardiology conference? To get started, review our list of upcoming Fellows courses, annual updates, case reviews, forums and more. And for additional events, we recommend checking out our database of Interventional Cardiology and Vascular Disease conferences.

More than 78 percent of health care personnel (HCP) and 53.6 percent of pregnant women received influenza vaccination during the 2016-2017 influenza season, according to two studies published in the Sept. 29 issue of Morbidity and Mortality Weekly Report. Carla L. Black, Ph.D., from the U.S. Centers for Disease Control and Prevention (CDC), and colleagues surveyed 2,438 HCP to estimate influenza vaccination coverage. The researchers found that during the 2016-2017 season, 78.6 percent of survey respondents reported receiving vaccination, similar to reported coverage in the previous three seasons. Coverage was highest for those working in hospitals compared with those working in ambulatory or long-term-care settings (92.3 versus 76.1 and 68 percent) and for those who were required by their employer to be vaccinated (96.7 percent), as in previous seasons. Helen Ding, M.D., from the CDC, and colleagues surveyed 1,893 women pregnant at any time during October 2016 to January 2017. The researchers found that 53.6 percent of respondents reported having received influenza vaccination before or during pregnancy (16.2 and 37.4 percent, respectively); this was similar to coverage during the previous four influenza seasons. Overall, 67.3, 11.9, and 20.7 percent of women reported receiving a provider offer for influenza vaccination, receiving a recommendation but no offer, and receiving no recommendation, respectively, similar to the previous influenza season; influenza vaccination coverage was 70.5, 43.7, and 14.8 percent, respectively, among these women.

Intensive blood pressure lowering may similarly decrease cardiovascular events in both patients with and patients without type 2 diabetes mellitus, according to a study published online Dec. 6 in Diabetes Care. Tom F. Brouwer, M.D., from the University of Amsterdam, and colleagues assessed the effect of both type 2 diabetes and baseline cardiovascular disease risk on the treatment effect of intensive blood pressure lowering based on data and pooled analysis from two randomized trials (ACCORD-BP [Action to Control Cardiovascular Risk in Diabetes Blood Pressure]and SPRINT [Systolic Blood Pressure Intervention Trial] studies; total of 14,094 patients). The researchers found that the mean baseline systolic blood pressure was 139.5 mm Hg for the cohort and just over one-third (33.6 percent) had type 2 diabetes. The hazard ratio for the primary composite end point of unstable angina, myocardial infarction, acute heart failure, stroke, and cardiovascular death was 0.82 (P = 0.0017). There was a nonsignificant interaction between intensive blood pressure lowering and type 2 diabetes (P = 0.13). While the 10-year cardiovascular risk was higher in patients with type 2 diabetes, there was no interaction between the risk and treatment effect (P = 0.84).

A new screening tool can adequately detect risk of diabetic retinopathy in adults with diabetes in low-income communities in Mexico, according to a study published in the October issue of Preventing Chronic Disease. Kenny Mendoza-Herrera, from the National Institute of Public Health in Mexico, and colleagues analyzed biochemical, clinical, anthropometric, and sociodemographic information from 1,000 adults with diabetes in low-income communities in Mexico in order to develop a screening tool based on a predictive model for early detection of diabetic retinopathy. Time since diabetes diagnosis, high blood glucose levels, systolic hypertension, and physical inactivity were risk factors included in the screening tool. The researchers found that the model had a mean area under the receiver operating characteristic curve (AUC ROC) of 0.78 in the validation data set. Using the optimized cut point that best represented the study population, the model had a sensitivity of 82.9 percent and a specificity of 61.9 percent. "We developed a low-cost and easy-to-apply screening tool to detect people at high risk of diabetic retinopathy in Mexico," the authors write. "Although classification performance of our tool was acceptable (AUC ROC > 0.75), error rates (precision) depend on false-negative and false-positive rates. Therefore, confirmatory assessment of all cases in mandatory."

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C. Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up. The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.

As an emergency medicine physician, you provide initial care for patients with acute illnesses or injuries. Your medical expertise is wide-ranging, so that you are able to quickly diagnose and begin interventions for a variety of conditions. Just as time cannot be wasted when you are with patients, and we do not feel your valuable time should be wasted while searching for required continuing medical education (CME). Our comprehensive database allows you to quickly and easily search, register and even book travel plans for emergency medicine conferences all in one place. Are you looking for CME regarding wilderness medicine? Emergency airway management? Infectious disease control? Palliative medicine ? Find the emergency medicine CME you need by searching our list of events, hosted by leaders in medicine such as Harvard Medical School . Are you ready to attend your next emergency medical conference? Review our list of upcoming conventions, annual updates, courses and more. And for additional events specific to common sub-specialties, check out our database of Critical Care Medicine ,Sports Medicine and Toxicology conferences .

For patients undergoing right heart catheterization (RHC), borderline pulmonary hypertension (PH) is associated with increased risk of mortality, according to a study published online Oct. 25 in JAMA Cardiology. Tufik R. Assad, M.D., from Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues conducted a retrospective cohort study involving patients undergoing routine RHC for clinical indication. Patients were classified according to mean pulmonary arterial pressure (mPAP) values as reference, borderline PH, and PH (mPAP values of ≤18, 19 to 24, and ≥25 mmHg, respectively). The researchers found that the prevalence of PH and borderline PH was 62 and 18 percent, respectively, among 4,343 patients. Independent associations were seen for advanced age, features of the metabolic syndrome, and chronic heart and lung disease with increased likelihood of borderline PH versus reference patients. Borderline PH was correlated with increased mortality compared with reference patients after adjustment for 34 variables (hazard ratio, 1.31). With higher mPAP there was an incremental increase in the risk of death, without an observed threshold. Sixty-one percent of the 70 patients with borderline PH who underwent repeated RHC had developed overt PH, with a 5 mmHg median increase in mPAP (interquartile range, -1 to 11 mmHg; P < 0.001).

American College of Emergency Physicians (ACEP) Scientific Assembly is organized by American College of Emergency Physicians (ACEP) and would be held during Oct 29 - Nov 01, 2017 at Walter E. Washington Convention Center, Washington, Dist of Col, United States of America. The target audience for this medical event for Emergency Physicians, Emergency Nurses, Nurse Practitioners, Residents and Fellows, Medical Students. This cme conference has been approved with a maximum of 29 AMA PRA Category 1 Credits. This Course will consist of clinical, as well as essential management and risk management tools to aid in your day-to-day practice. With educational courses, skills labs and workshops - ACEP17 is the best source for your emergency medicine education needs! Conference Objectives are : * Abdominal Disorders * Airway, Anesthesia, Analgesia * Cardiovascular * Career Advancement Through Teaching * Critical Care * Critical ED Management * Dematologic Disorders * Emergency Imaging * Head & Neck Disorders * Health Policy * Hematologic Disorders * Infectious Disease * Knowledge Translation * Maintenance of Certification * Metabolic and Endocrine Disorders * Neurology * New Technology * Orthopedics and Sports Medicine * Pediatric Disorders

American College of Emergency Physicians (ACEP) Scientific Assembly is organized by American College of Emergency Physicians (ACEP) and would be held during Oct 29 - Nov 01, 2017 at Walter E. Washington Convention Center, Washington, Dist of Col, United States of America. The target audience for this medical event for Emergency Physicians, Emergency Nurses, Nurse Practitioners, Residents and Fellows, Medical Students. This cme conference has been approved with a maximum of 29 AMA PRA Category 1 Credits. This Course will consist of clinical, as well as essential management and risk management tools to aid in your day-to-day practice. With educational courses, skills labs and workshops - ACEP17 is the best source for your emergency medicine education needs! Conference Objectives are : * Abdominal Disorders * Airway, Anesthesia, Analgesia * Cardiovascular * Career Advancement Through Teaching * Critical Care * Critical ED Management * Dematologic Disorders * Emergency Imaging * Head & Neck Disorders * Health Policy * Hematologic Disorders * Infectious Disease * Knowledge Translation * Maintenance of Certification * Metabolic and Endocrine Disorders * Neurology * New Technology * Orthopedics and Sports Medicine * Pediatric Disorders * Prehospital / Disaster Medicine * Professional Skills * Pulmonary Disorders * Risk Management / ED and Law * Toxicology / Environmental * Trauma * Urologic and OB/GYN ACEP17 is the must attend event for anyone engaged in the practice of emergency medicine, including : * Emergency Physicians * Nurse Practitioners * Residents * Medical Students * Physician Assistant * Emergency Department Medical Directors * Hospital Administrators * EMTs/Paramedics

American College of Allergy, Asthma & Immunology (ACAAI) Precision Medicine in Allergy Practice Annual Scientific Meeting is organized by American College of Allergy, Asthma and Immunology (ACAAI) and would be held during Oct 26 - 30, 2017 at Hynes Convention Center, Boston, Massachusetts, United States of America.

Arthritis was thought to be a disease that happens to older people. But not anymore! Today, it can affect people of any age group. And thanks to the legalization of cannabis, you can now treat your arthritis with cannabis provided you have a medical marijuana card in Anaheim.